In a far reaching agreement, Zydus Cadila has entered into a long term strategic pact with Boehringer Ingelheim India Private Limited, a Wholly Owned Subsidiary (WOS) of Boehringer Ingelheim, a research-driven pharmaceutical company with headquarters in Germany. According to the agreement, Zydus Cadila will continue to manufacture and market, in India, Boehringer Ingelheim's products such as Dulcolax and Buscopan in the gastrointestinal and Actilyse in the cardiovascular segments and these are brand leaders in their respective therapeutic areas.

Boehringer Ingelheim was one of the key collaborators in the erstwhile German Remedies Ltd. Over the last 40 years, products of Boehringer Ingelheim have been manufactured and marketed by German Remedies, which has since merged with Cadila Healthcare Limited. With this strategic pact between the two companies, Zydus Cadila will continue to manufacture and market products of Boehringer Ingelheim for a period of 10 years. By mutual consent, the agreement may be extended for a further period of five years. The products will be manufactured at Zydus Cadila's state-of-the-art manufacturing plant at Moraiya in Ahmedabad which is approved by some of the world's leading regulatory authorities including MCA of UK and MCC of South Africa.

The long term agreement between the two companies follows the setting up of a wholly owned subsidiary, Boehringer Ingelheim India Private Limited. Given the future potential of the Indian pharmaceutical industry, Boehringer Ingelheim will use the Indian subsidiary as a vehicle to expand the company's scientific and business presence in India. To build on their respective strengths and establish a mutually beneficial win-win partnership, Zydus Cadila and Boehringer Ingelheim India Pvt. Ltd. will further explore a joint venture or other strategic alliances to manufacture and market, in India, new products of Boehringer Ingelheim.

The Boehringer Ingelheim Group ranks amongst the 20 leading pharmaceutical corporations in the world. Headquartered in Ingelheim, Germany, the BI group operates globally with 156 affiliates in 44 countries and employs around 32,000 people.